Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 204

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies

Open access
Fischbach, L. A., van Zanten, S. V., Dickason, J. · 2004 · Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background : Owing to rising drug‐resistant Helicobacter pylori infections, currently recommended proton‐pump inhibitor‐based triple therapies are losing their efficacy, and regimens efficacious in the presence of drug resistance are needed. Aims : To summarize the efficacy, safety and adherence of first‐line quadruple H. pylori therapies in adults. Methods : Meta‐regression models identified factors explaining variation in the efficacy of first‐line quadruple therapies from 145 treatment arms. Estimates of average efficacy were calculated within homogeneous groups. Results : Quadruple therapy containing a gastric acid inhibitor, bismuth, metronidazole and tetracycline was enhanced when omeprazole was included, treatment duration lasted 10–14 days, and when therapy took place in the Netherlands, Hong Kong and Australia. Treatment efficacy decreased as the prevalence of metronidazole resistance increased. Even in areas with a high prevalence of metronidazole resistance, this quadruple regimen eradicated more than 85% of H. pylori infections when it contained omeprazole and was given for 10–14 days. Furthermore, in the presence of clarithromycin resistance, this quadruple regimen eradicated 90–100% of H. pylori infections, while the currently recommended triple therapy containing clarithromycin, amoxicillin and a proton‐pump inhibitor eradicated only 25–61% (P < 0.001). Adherence and adverse events for quadruple therapy were similar to currently recommended triple therapies. Conclusions : Guidelines should include quadruple therapy with a proton‐pump inhibitor, a bismuth compound, metronidazole and tetracycline among recommended first‐line anti‐H. pylori therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02248.x

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 204

Metadata

Authors
Fischbach, L. A., van Zanten, S. V., & Dickason, J.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2004-11
Volume
20
Issue
10
Pages
1071-1082
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2079175995
Cited by
204
References
6
FWCI
11.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies. https://app.cochat.ai/papers/10.1111/j.1365-2036.2004.02248.x
The paper
Fischbach, L. A., van Zanten, S. V., & Dickason, J. (2004). Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2004.02248.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.